US Patent

US11246866 — Solid pharmaceutical compositions for treating HCV

Formulation · Assigned to AbbVie Inc · Expires 2036-06-24 · 10y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects solid pharmaceutical compositions containing Compound 1 and Compound 2, specifically a two-layer formulation with 100 mg of Compound 1 and 40 mg of Compound 2.

USPTO Abstract

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Drugs covered by this patent

Patent Metadata

Patent number
US11246866
Jurisdiction
US
Classification
Formulation
Expires
2036-06-24
Drug substance claim
No
Drug product claim
Yes
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.